BioSpace News Archive

Policy

Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American

Navidea Biopharmaceuticals, Inc. today announced settlement of the ongoing litigation with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”).

February 3, 2022

·

5 min read

Zymeworks Announces Participation in Upcoming Investor Conferences - Feb 03, 2022

Zymeworks Inc. announced that management will participate in upcoming investor conferences.

February 3, 2022

·

2 min read

FDA

Clinical Trial Research at Wolfe Eye Clinic contributes to FDA Approval of Genentech’s Vabysmo ™, the First Bispecific Antibody for the Eye, Treating Two Vision Loss Causes

In a press release Friday, Genentech announced approval of Vabysmo™ (faricimab-svoa), a new advancement in the treatment approach for Wet Age-Related Macular Degeneration (AMD) and diabetic macular edema (DME).

February 3, 2022

·

4 min read

Bone Allografts and Xenografts Industry Size 2021-2028 - Rising Demand For A Variety Of Orthopaedics Operations Is One Of The Main Factors Expected To Drive Market Revenue Growth, Says Reports and Data

The industry analysis report is considered a valuable source of information about the global Bone Allografts and Xenografts industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

February 3, 2022

·

7 min read

Rising Demand For Sodium Hypophosphite As A Reducing Agent In Water Treatment Facilities And Growing Usage in Pharmaceuticals Industry – Reports and Data

The global Sodium Hypophosphite market research report is a comprehensive report published by Reports and Data that evaluates the market size and share, growth opportunities, risks and limitations, and market growth curve.

February 3, 2022

·

5 min read

Pharm Country

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 03, 2022

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced grants of stock options and Restricted Stock Units to five new employees.

February 3, 2022

·

2 min read

Business

Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT.

February 3, 2022

·

2 min read

Business

LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021.

February 3, 2022

·

22 min read

Business

Silk Road Medical to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

Silk Road Medical, Inc. today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022.

February 3, 2022

·

1 min read

BioCapital

New Zealand’s Medsafe Grants Provisional Approval for Novavax’ COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), today announced that New Zealand’s Medsafe has granted provisional approval of NVX-CoV2373, Novavax’ COVID-19 vaccine (adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older.

February 3, 2022

·

11 min read